Research Priorities - Cancer
  • Article
  • Dec 6 2021

The summer program encourages more young women of diverse backgrounds to seek out careers in science and medicine.

  • Article
  • Nov 2 2021

A recent study shows that patients with non-small cell lung cancer reviewed by the University of Kentucky Markey Cancer Center’s Molecular Tumor Board experience improved outcomes, even if they reside in rural Appalachian Kentucky.

  • Video
  • Oct 22 2021

The Markey STRONG Scholars Program fosters diversity in cancer research. The 10-week program that aims to provide career and professional development for college sophomores, juniors and seniors.

  • Article
  • Oct 21 2021

A recent College of Medicine study found young adults from vulnerable communities are more likely to be exposed to tobacco marketing in their daily lives.

  • Article
  • Oct 21 2021

The funds from the American Cancer Society will help alleviate the financial burden of transportation costs for cancer patients throughout Kentucky.

  • Article
  • Oct 6 2021

A new study from the lab of Markey Cancer Director Mark Evers, M.D., demonstrates the critical role of the hormone neurotensin in cell proliferation and stem cell function in the small intestine.

  • Article
  • Sep 28 2021

A recent study demonstrates that a combination of two drugs used together provides better than expected results, providing a promising treatment strategy for patients with recurrent ovarian cancer.

  • Article
  • Sep 2 2021

Lt. Gov. Coleman and several of Kentucky’s female legislators joined UK HealthCare to highlight the work of the Markey Cancer Center's Ovarian Cancer Screening Program.

  • Article
  • Aug 17 2021

The initiative aims to create a connected, integrated statewide cancer provider network. 40% of all new cancer cases in Kentucky are directly or indirectly cared for by Markey.

  • Video
  • Apr 26 2021

The UK Markey Cancer Center has officially launched a unique new clinical trial to test whether Artemisia annua extract can prevent ovarian cancer recurrence.